Requires health insurance coverage for testing for BRCA1 and BRCA2 genes.
Impact
If enacted, A2332 will significantly alter existing state laws concerning health insurance coverage for genetic testing. It positions such testing as a necessary medical benefit indistinguishable from other treatments, thereby ensuring that individuals who may be at increased genetic risk for breast cancer are afforded the opportunity to take proactive health measures. The law will apply to various health insurance contracts issued within the state, thereby enhancing access to essential medical services for affected individuals.
Summary
Assembly Bill A2332 mandates that health insurance carriers in New Jersey provide coverage for testing associated with the BRCA1 and BRCA2 genes, which are linked to breast cancer risk. This legislation is aimed at ensuring that individuals with health insurance policies can access genetic testing without facing additional financial burdens. By requiring these carriers to include such benefits in their contracts, the bill seeks to improve early detection measures for breast cancer and further promotes preventive healthcare practices among policyholders.
Contention
While there is a general consensus on the importance of genetic testing for breast cancer, there may be debates surrounding the financial implications for insurance companies and the potential for higher premiums as a result of expanded coverage. Some stakeholders could argue that such mandated coverage could lead to increased costs that insurers may pass on to consumers. Additionally, there may be discussions about the necessity of requiring testing as a covered benefit in relation to the broader healthcare system and its existing financial frameworks.
In casualty insurance, repealing provisions relating to coverage for mammographic examinations and breast imaging and providing for coverage for mammographic examinations, magnetic resonance imaging and other forms of breast imaging.